Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies

Mise à jour : Il y a 4 ans
Référence : NCT01463982

Femme et Homme

Extrait

The main objective of this study is to determine the maximum tolerated dose (MTD) of Oratecan in combination with capecitabine


Critère d'inclusion

  • Solid tumor ,advanced cancer

Liens